Compare RFL & RSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RFL | RSF |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Investment Managers |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 59.0M |
| IPO Year | 2017 | N/A |
| Metric | RFL | RSF |
|---|---|---|
| Price | $1.99 | $14.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 83.8K | 10.6K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.61% |
| EPS Growth | ★ 28.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $14.23 |
| 52 Week High | $2.70 | $15.07 |
| Indicator | RFL | RSF |
|---|---|---|
| Relative Strength Index (RSI) | 86.90 | 50.65 |
| Support Level | $1.22 | $14.61 |
| Resistance Level | N/A | $14.70 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 89.64 | 48.47 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.